Concepedia

Author

Ana Yuste

Hospital General Universitario de Alicante Doctor Balmis

Also Known As

Ana L Yuste, Ana L. Yuste, Ana Lucia Yuste, Ana Yuste, Jordi Giralt

28

Publications

302

Citations

9

H-Index

15

Concepts

All Affiliations

Hospital General Universitario de Alicante Doctor BalmisHospital General Universitario de ElcheMarqués de Valdecilla University HospitalInstitut Català d'OncologiaHospital Universitario Reina Sofía
AY

About

Ana Yuste is an author at Hospital General Universitario de Alicante Doctor Balmis specializing in oncology, surgical oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

83

2

Gastroenterology

2

2

46

3

Pathology

2

2

48

4

Health Sciences

1

1

11

5

Hepatology

1

1

11

Ana Yuste

×

7

Publications

218

Citations

7

H-Index

YearCitations

Pulmonary Fibrosis Induced by Cyclophosphamide

Ángel Segura, Ana Yuste, Ana C Cercós,

Annals of Pharmacotherapy

2001

57

Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy

Óscar Murcia, Míriam Juárez, María Rodríguez–Soler,

PLoS ONE

2018

45

Analysis of Clinical Prognostic Factors for Survival and Time to Progression in Patients with Metastatic Colorectal Cancer Treated with 5-Fluorouracil—Based Chemotherapy

Ana Yuste, Jorge Aparicio, Ángel Segura,

Clinical Colorectal Cancer

2003

37

Phase II Trial of Preoperative Irinotecan–Cisplatin Followed by Concurrent Irinotecan–Cisplatin and Radiotherapy for Resectable Locally Advanced Gastric and Esophagogastric Junction Adenocarcinoma

Fernando Rivera, Maica Galán, Josep Tabernero,

International Journal of Radiation Oncology*Biology*Physics

2009

35

Toxic Epidermal Necrolysis Associated with Interleukin-2

Angel A Segura Huerta, Pablo Tordera, Ana C Cercós,

Annals of Pharmacotherapy

2002

17

Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study

Albert Abad, Bartomeu Massutí, Antonio Antón,

Acta Oncologica

2008

16

Phase II trial of panitumumab plus FOLFOX4 or FOLFIRI in subjects with KRAS wild-type colorectal cancer and liver-limited disease: The PLANET study.

Albert Abad, Bartomeu Massutí, Cristina Grávalos,

Journal of Clinical Oncology

2014

11

Page 1